glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Coach Colin Watson on Retatrutide: 12-Week Review vs What the Data Shows

Part of YouTube & Expert Fact Checks.

Coach Colin Watson on Retatrutide: 12-Week Review vs What the Data Shows

Weight loss coach Colin F. Watson published a video titled "Is RETATUTIDE Worth The RISK? NEW GLP-3" sharing his 12-week experience with grey market retatrutide. He describes a coaching business and a financial interest in a peptide seller; the current video description promotes ChainX Peptides. He describes losing 11 pounds, dropping from 13.8% to 10.9% body fat, and calls retatrutide "probably the most powerful fat loss peptide on the planet."
This review uses the published video description and automated transcript of the November 14, 2025 video. It separates his personal account from trial evidence, including results released after the video. Watson states the video is for educational purposes only and that he is not telling anyone to use retatrutide.

The Triple Mechanism: Garbled Explanation

The transcript describes three pathways but confuses receptor names and assigns glucagon a role in keeping someone in a “fat burning zone.” Automated transcription may account for some garbled names; it cannot validate the physiology.

Retatrutide targets GIP, GLP-1 and glucagon receptors. GLP-1 activity contributes to appetite reduction and delayed gastric emptying; GIP is an incretin involved in glucose-dependent insulin secretion. Glucagon can increase hepatic glucose output. Its contribution to retatrutide’s metabolic effects is more complex than keeping insulin low.
The mechanism study includes preclinical evidence on food intake and energy expenditure. It does not establish a measurable “fat burning zone” in humans or prove that insulin alone determines fat loss. See How Retatrutide Works and GLP-1 vs GLP-3.

"Most Powerful Fat Loss Peptide on the Planet"

Watson’s superlative is an opinion, not a conclusion his personal experiment can establish. The later TRIUMPH-4 release, published after his video, reported 28.7% average weight loss at 68 weeks with 12 mg in adults with obesity and knee osteoarthritis, using the efficacy estimand. The treatment-regimen analysis reported 23.7%.
These results are substantial, but weight loss is not identical to fat loss, and a placebo-controlled trial cannot establish superiority to every other medicine. See Retatrutide Results for the trial-specific evidence.

His Personal Results

Watson reports losing 11 pounds over 12 weeks, with body fat changing from 13.8% to 10.9% at age 64. He describes some visceral-fat loss and roughly 3.5–4 pounds of lean-mass loss, which he attributes to difficulty eating enough protein. He also mentions hydration as a possible factor.

Those are self-reported measurements. The transcript does not provide a standardized measurement method, verified product composition or a controlled comparison. Visceral fat is part of body fat; lean mass is not identical to skeletal muscle.

He says his dose reached 5 mg. That is not below every Phase 3 target dose: the TRIUMPH program includes a 4 mg target. It still does not make his regimen equivalent to a monitored trial. Trial group averages cannot confirm why his weight or body composition changed. See the trial dosing overview.

Muscle Preservation Claim

Watson says retatrutide preserves muscle better than other GLP-1 drugs and characterizes their losses as mostly lean tissue and water. His personal account does not establish either claim.

The published retatrutide DXA substudy involved people with type 2 diabetes, with 189 enrolled and 103 completing treatment plus baseline and week-36 scans. Its 26.1% figure was a reduction in total fat mass in the pooled 8 mg group, not the proportion of weight loss that was lean mass.
The authors found that the proportion of lean-mass loss was broadly consistent with other obesity treatments. The study did not directly compare retatrutide with tirzepatide or semaglutide, and it does not establish superior preservation of skeletal muscle. See Retatrutide and Muscle Loss.

Side Effects: "Not Really Any"

Watson says he and his clients experienced essentially no side effects except appetite suppression: "None of the nausea... the only downside I'm seeing right now is that it's difficult for them to eat."

His account cannot establish the general adverse-event rate. The later TRIUMPH-4 sponsor release reports the following at 12 mg:

Swipe sideways to see every column.

Side EffectTRIUMPH-4 (12 mg)PlaceboVerdict
Nausea43.2%10.7%Very common
Diarrhea33.1%13.4%Common
Constipation25.0%8.7%Common
Vomiting20.9%0.0%Common
Dysesthesia (skin sensations)20.9%0.7%Reported in Phase 2 and Phase 3

In Phase 3, 43% of participants experienced nausea and 21% experienced vomiting at the 12 mg dose. Dysesthesia was also reported in Phase 2; it was not first discovered in Phase 3. In TRIUMPH-4 dysesthesia events were generally mild and rarely caused discontinuation. Overall adverse-event discontinuation was 18.2% at 12 mg versus 4.0% with placebo. Watson’s experience cannot establish that others will have few side effects, and dose alone does not explain the difference.

For the full safety profile, see Retatrutide Side Effects.

The "Hypothalamic Set Point Reset" Claim

Watson suggests retatrutide might repair the hypothalamic loop and help maintain a new weight, while acknowledging that the research is not settled. The trials summarized here do not establish a permanent reset or lasting weight maintenance after stopping retatrutide.

Evidence from other medicines supports caution without proving a retatrutide-specific outcome. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% of their week-36 body weight over the next 52 weeks. That is not “14% of the weight they had lost.”

Weight regain does not by itself measure hypothalamic repair. A retatrutide withdrawal study would need to establish the post-treatment outcome rather than infer it from a proposed mechanism.

The Peptide Seller Conflict

Watson discloses a commercial interest in a research-peptide business and promotes an app. The current video description links to ChainX Peptides. That financial interest is relevant when assessing recommendations about a product he sells.

The transcript does not independently verify the product’s identity or quality. His self-experiment cannot substitute for the controlled trial evidence. See Grey Market Retatrutide.

Frequently Asked Questions

Who is Coach Colin Watson?

Colin F. Watson describes himself as a weight-loss coach. In the November 2025 video he discusses his own peptide use and discloses a commercial peptide business; the current description promotes ChainX Peptides. This review does not independently verify his professional credentials.

Is his review trustworthy?

It is a personal account with a disclosed commercial interest, not controlled medical evidence. Claims about superior muscle preservation and a lasting hypothalamic reset are not established by the studies reviewed here. Automated transcript errors also limit precise attribution of receptor names.

Did retatrutide really work for him?

He reports 11 pounds lost over 12 weeks and a dose reaching 5 mg. Without verified product identity, standardized measurements and a control group, the account cannot establish how much of the change was caused by retatrutide.

Can you microdose retatrutide like Watson describes?

He reports trying different dosing patterns, but his experience does not validate a microdosing regimen. A 5 mg maximum is not below every Phase 3 target: the program includes 4 mg. Trial protocols are monitored research regimens, not instructions for self-treatment. See Microdosing Retatrutide.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all fact checks topics →